ArticleJournal of hematology & oncology2016

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.

Xuejiao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.